Skip to main content

Urinary micro RNA pattern as marker for early breast cancer diagnosis

Ref-Nr: TA-ZEE20150317


Kurzfassung

Non-invasive, hazard-free detection of early breast cancer in urine


Hintergrund

Since recent studies revealed the feasibility to detect blood-based microRNAs (miRNAs, miR) in breast cancer (BC) patients a new field has been opened for circulating miRNAs as potential biomarkers in BC. In this pilot study, we evaluated to our knowledge for the first time whether distinct pattern of urinary miRNAs might be also applicable as innovative biomarkers for BC detection.


Problemstellung

Breast cancer (BC) represents the most frequent malignant disease in women worldwide. In Germany 72.000
cases are diagnosed each year (worldwide appr. 1.2 million women). Detection of BC is based on clinical
symptoms (e.g. lumps) or established screening programs for detection of early disease by mammography. Early
detection is crucial for improved curation rates and minimization of therapeutical procedures (surgery,
chemotherapy). However, screening with X-rays is controversially discussed and participation rates are
suboptimal due to the exposure to radiation doses and their potential harmful biological effects.
MicroRNAs (miRNAs) are small (< 30 basepairs) non-coding RNAs with multiple crucial functions also in breast
cancer as tumor promoting as well as tumor suppressing factors. We developed an unique urine-based miRNA
assay (9 specific miRNAs) to detect early, primary breast cancer


Lösung

  • Quantification of 9 miRNAs in midstream urine (5ml) with a specific expression pattern to detect early breast cancer
  • High sensitivity and specificity (detection rate: > 90%)
  • Non-invasive and hazard-free

Vorteile

  • Assay fully developed
  • For immediate application
  • Only standard equipment and technology (realtime PCR) required

Anwendungsbereiche

  • Screening for breast cancer as part of an innovative multiple step concept to avoid unnecessary diagnostic work up and radiation exposure
  • Tool for follow-up after breast cancer treatment for detection of recurrences
  • Monitoring of treatment response in the neoadjuvant and metastatic setting

Service

Responsible Scientist
Prof. Dr. Elmar Stickeler, Dept. OB/Gyn, RWTH Aachen University

Contact
Dr. Claudia Skamel
Campus Technologies Freiburg GmbH
Stefan-Meier-Str. 8, D-79104 Freiburg
Email: claudia.skamel@campus-technologies.de
Tel: +49 (0)761 203-4987
Fax:+49 (0)761 203-5021


Campus Technologies Freiburg GmbH

Dr. Claudia Skamel
+49 (0) 761/203 499 0
claudia.skamel@campus-technologies.de
www.campus-technologies.de
Adresse
Stefan-Meier-Str. 8
79104 Freiburg



Entwicklungsstand

Marktreife


Patentsituation

  • EP anhängig

Angebot Anbieter-Website


Kontakt | Geschäftsstelle

TechnologieAllianz e. V.
Laure Wolkers
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr